

## **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims**

1. (Currently amended) A method of expanding a population of hematopoietic stem cells, the method comprising steps of:  
providing at least one stem cell with less than wild type p21 activity and a lack of inhibition of p27 activity; and  
expanding the cell population.
2. (Currently amended) The method of claim 1, wherein the step of providing comprises: providing a hematopoietic stem cell; and  
disrupting the cell's p21 gene.
3. (Currently amended) The method of claim 1, wherein the step of providing comprises: providing a hematopoietic stem cell; and  
contacting the cell with an agent, wherein the agent inhibits p21 activity.
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)

9. (Canceled)
10. (Previously presented) The method of claim 1, wherein the cell is an erythropoietic cell.
11. (Previously presented) The method of claim 1, wherein the cell is a granulopoietic cell.
12. (Previously presented) The method of claim 1, wherein the cell is a thrombopoietic cell.
13. (Canceled)
14. (Canceled)
15. (Previously presented) The method of claim 1, wherein the cell is an adult-derived stem cell.
16. (Previously presented) The method of claim 1, wherein the cell is an embryonically derived stem cell.
17. (Previously presented) The method of claim 1, wherein the cell is a pluripotent stem cell.
18. (Previously presented) The method of claim 1, wherein the cell is a multi-potential stem cell.
19. (Previously presented) The method of claim 1, wherein the cell is a fetal cell.

- |     |                        |   |
|-----|------------------------|---|
| 20. | (Previously presented) | The method of claim 1, wherein the cell is an embryonic cell.   |
| 21. | (Previously presented) | The method of claim 1, wherein the cell is a mesenchymal cell.  |
| 22. | (Previously presented) | The method of claim 3, wherein the agent is a protein.  |
| 23. | (Previously presented) | The method of claim 3, wherein the agent is a peptide.  |
| 24. | (Previously presented) | The method of claim 3, wherein the agent is a polynucleotide.   |
| 25. | (Previously presented) | The method of claim 3, wherein the agent is a chemical compound.  |
| 26. | (Previously presented) | The method of claim 3, wherein the agent is an antibody or fragment thereof.  |
| 27. | (Previously presented) | The method of claim 3, wherein the agent is an antisense agent.   |
| 28. | (Previously presented) | The method of claim 3, wherein the agent is a triple helix forming agent.   |
| 29. | (Previously presented) | The method of claim 3, wherein the agent is an aptamer.   |
| 30. | (Previously presented) | An isolated stem or progenitor cell with less than wild type p21 activity and a lack of inhibition of p27 activity. |

31. (Previously presented) The stem or progenitor cell of claim 30 with at least one copy of the p21 gene disrupted.
32. (Previously presented) The stem or progenitor cell of claim 30 with both copies of the p21 gene disrupted.
33. (Canceled)
34. (Canceled)
35. (Canceled)
36. (Original) The cell of claim 30, wherein the cell is a stem cell.
37. (Original) The cell of claim 30, wherein the cell is a progenitor cell.
38. (Canceled)
39. (Canceled)
40. (Canceled)
41. (Canceled)
42. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the cells of claim 30, wherein the cells are hematopoietic cells.
43. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the stem cells of claim 36, wherein the cells are hematopoietic cells.

44. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the progenitor cells of claim 37, wherein the cells are hematopoietic cells.

45. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the cells of claim 30, wherein the cells are hematopoietic cells; and a pharmaceutically acceptable excipient.

46-74. (Canceled)

75. (Previously presented) The method of claim 3, wherein the agent is an RNA inhibiting agent.